A Study of AK104 With Chemotherapy as First-line Treatment in Patients With Advanced Pancreatic Cancer
Status:
Not yet recruiting
Trial end date:
2025-06-01
Target enrollment:
Participant gender:
Summary
This study is a multicenter, open-label, phase II study to evaluate the safety, tolerability,
pharmacokinetics (PK), immunogenicity, pharmacodynamics (PD) and anti-tumor activities of
AK104，a PD-1/CTLA-4 bispecific antibody, in combination with gemcitabine and nab-paclitaxel
as first-line therapy in subjects with advanced unresectable or metastatic pancreatic ductal
adenocarcinoma.